ReNeuron
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
ReNeuron - overview
Location
Guildford, -, UK
Primary Industry
Biotechnology
About
ReNeuron is a biotechnology company focused on advancing precision medicine through its innovative CustomEX™ drug delivery platform, which utilizes engineered stem cells for targeted therapeutic applications. ReNeuron develops advanced exosome drug delivery solutions aimed at improving therapeutic efficacy and precision. Founded in Guildford, UK, ReNeuron has not undergone significant pivots in its business strategy. The company's focus remains on partnerships and collaborations within the pharmaceutical and research sectors, which have been crucial for its growth.
The current CEO is unknown, and there is no information available regarding the founder's history or previous ventures. ReNeuron specializes in advancing precision medicine through its flagship product, CustomEX™, a customizable exosome drug delivery platform derived from engineered stem cells. This innovative platform is designed to enhance targeted therapeutic delivery, facilitating the transportation of therapeutic agents in a highly efficient manner. ReNeuron aims to address a range of medical challenges, particularly in the fields of regenerative medicine and targeted therapeutics, by improving the efficacy and precision of drug delivery systems.
The company primarily serves pharmaceutical companies, research institutions, and healthcare providers looking for advanced solutions in drug delivery. Geographically, ReNeuron markets its products across multiple regions, including North America, Europe, and parts of Asia, catering to an international clientele focused on biomedical research and treatment development. In 2023, ReNeuron reported a revenue of USD 639,049. 70 and an EBITDA of USD -8,257,004.
90. The company generates revenue through strategic partnerships and collaborations with pharmaceutical firms and research institutions, primarily centered around their CustomEX™ platform. Transactions typically occur on a B2B basis, where clients engage ReNeuron for tailored drug delivery solutions that meet specific therapeutic needs. The revenue structure includes licensing agreements and development contracts that facilitate the integration of CustomEX™ into clients' product pipelines, along with milestone payments tied to the achievement of development phases and potential royalties based on product sales.
ReNeuron is focused on expanding its CustomEX™ platform to new markets and enhancing its product offerings. The company is actively designing new applications for CustomEX™, aimed at addressing diverse therapeutic areas. As part of its growth strategy, ReNeuron plans to enter additional regions, including areas in Asia and North America, by the end of 2024. Recent funding rounds will support these initiatives, particularly in expanding their R&D capabilities, enhancing product development, and pursuing strategic partnerships to broaden their market reach.
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Pharmaceutical Research & Development
Website
www.reneuron.com
Total Amount Raised
Subscriber access only
ReNeuron - timeline of key events
ReNeuron - financials
| Fiscal Year Ended | Mar 31, 2011 | Mar 31, 2012 | Mar 31, 2013 | Mar 31, 2014 | Mar 31, 2015 | Mar 31, 2016 | Mar 31, 2017 | Mar 31, 2018 | Mar 31, 2019 | Mar 31, 2020 | Mar 31, 2021 | Mar 31, 2022 | Mar 31, 2023 | Mar 31, 2024 | Mar 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 29,000 | 40,000 | 17,000 | 22,000 | 30,000 | 29,000 | 46,000 | 43,000 | 49,000 | 6,065,000 | 257,000 | 403,000 | - | - | - |
| % Revenue Growth (YoY) | - | 37.9% | (57.5%) | 29.4% | 36.4% | (3.3%) | 58.6% | (6.5%) | 14.0% | 12277.6% | (95.8%) | 56.8% | - | - | - |
| EBITDA (USD) | (6,512,000) | (6,734,000) | (6,966,000) | (7,857,000) | (10,269,000) | (13,632,000) | (19,718,000) | (20,144,000) | (18,000,000) | (13,997,000) | (12,534,000) | (10,904,000) | - | - | - |
| Operating Income (USD) | (6,666,000) | (6,884,000) | (7,088,000) | (7,969,000) | (10,394,000) | (13,724,000) | (19,887,000) | (20,376,000) | (18,282,000) | (14,409,000) | (12,914,000) | (11,228,000) | - | - | - |
| Operating Margin | (22986.2%) | (17210.0%) | (41694.1%) | (36222.7%) | (34646.7%) | (47324.1%) | (43232.6%) | (47386.0%) | (37310.2%) | (237.6%) | (5024.9%) | (2786.1%) | - | - | - |
| % EBITDA Margin | (22455.2%) | (16835.0%) | (40976.5%) | (35713.6%) | (34230.0%) | (47006.9%) | (42865.2%) | (46846.5%) | (36734.7%) | (230.8%) | (4877.0%) | (2705.7%) | - | - | - |
| NET Income (USD) | (6,148,000) | (6,229,000) | (6,345,000) | (7,066,000) | (8,906,000) | (11,354,000) | (15,573,000) | (17,615,000) | (14,292,000) | (11,412,000) | (11,347,000) | (9,689,000) | - | - | - |
| % Net Margin | (21200.0%) | (15572.5%) | (37323.5%) | (32118.2%) | (29686.7%) | (39151.7%) | (33854.3%) | (40965.1%) | (29167.3%) | (188.2%) | (4415.2%) | (2404.2%) | - | - | - |
ReNeuron - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.